Sotac Pharmaceuticals is a contract manufacturer that develops and produces a wide variety of generic medicines, including tablets, capsules, and syrups, for major pharmaceutical brands and healthcare providers.
The company operates in a highly fragmented contract manufacturing market with low barriers to entry, evidenced by thin net margins of 5.8%. While they possess WHO-GMP certifications and a diverse product portfolio, the lack of proprietary drug discovery and the decline in EPS despite revenue growth suggests a lack of durable pricing power or scale advantage.
Capital has been primarily directed toward expanding capacity and investing in subsidiaries like Sotac Healthcare and Sotac Lifesciences. While revenue has grown, the negative EPS CAGR suggests that recent reinvestments have yet to translate into bottom-line value for shareholders.
The investment collapsed as the company's aggressive capacity expansion failed to generate incremental profits, leading to a 'profitless growth' trap. Despite rising revenues, the inability to convert sales into cash—evidenced by a near-zero cash conversion ratio—forced the company into a liquidity crunch. The combination of rising overhead from subsidiaries and thin margins in a commoditized market eventually eroded the equity base, while the frequent turnover of independent directors foreshadowed a breakdown in oversight that left minority shareholders holding the bag for misallocated capital.
RichFakir rates Sotac Pharmaceuticals Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sotac Pharmaceuticals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sotac Pharmaceuticals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sotac Pharmaceuticals Ltd's fair value is about ₹53 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →